| CAMPO, E., F. CYMBALISTA, P. GHIA, U. JAGER, Šárka POSPÍŠILOVÁ, R. ROSENQUIST, A. SCHUH and S. STILGENBAUER. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2018, vol. 103, No 12, p. 1956-1968. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.187583. |
Other formats:
BibTeX
LaTeX
RIS
@article{1507037,
author = {Campo, E. and Cymbalista, F. and Ghia, P. and Jager, U. and Pospíšilová, Šárka and Rosenquist, R. and Schuh, A. and Stilgenbauer, S.},
article_location = {PAVIA},
article_number = {12},
doi = {http://dx.doi.org/10.3324/haematol.2018.187583},
keywords = {IN-SITU HYBRIDIZATION; OPEN-LABEL; MUTATION ANALYSIS; DISEASE PROGRESSION; CLONAL EVOLUTION; FOLLOW-UP; GENETIC-CHARACTERIZATION; GENOMIC ABERRATIONS; RECURRENT MUTATIONS; SEQUENCE VARIANTS},
language = {eng},
issn = {0390-6078},
journal = {haematologica},
title = {TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics},
volume = {103},
year = {2018}
}
TY - JOUR
ID - 1507037
AU - Campo, E. - Cymbalista, F. - Ghia, P. - Jager, U. - Pospíšilová, Šárka - Rosenquist, R. - Schuh, A. - Stilgenbauer, S.
PY - 2018
TI - TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
JF - haematologica
VL - 103
IS - 12
SP - 1956-1968
EP - 1956-1968
PB - FERRATA STORTI FOUNDATION
SN - 03906078
KW - IN-SITU HYBRIDIZATION
KW - OPEN-LABEL
KW - MUTATION ANALYSIS
KW - DISEASE PROGRESSION
KW - CLONAL EVOLUTION
KW - FOLLOW-UP
KW - GENETIC-CHARACTERIZATION
KW - GENOMIC ABERRATIONS
KW - RECURRENT MUTATIONS
KW - SEQUENCE VARIANTS
N2 - Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Clinical trials demonstrate the importance of accurately testing for TP53 aberrations [both del(17p) and TP53mutations] before each line of treatment to allow for appropriate treatment decisions that can optimize patients' outcomes. The current report reviews the diagnostic methods to detect TP53 disruption better, the role of TP53 aberrations in treatment decisions and current therapies available for patients with chronic lymphocytic leukemia carrying these abnormalities. The standardization in sequencing technologies for accurate identification of TP53 mutations and the importance of continued evaluation of TP53 aberrations throughout initial and subsequent lines of therapy remain unmet clinical needs as new therapeutic alternatives become available.
ER -
CAMPO, E., F. CYMBALISTA, P. GHIA, U. JAGER, Šárka POSPÍŠILOVÁ, R. ROSENQUIST, A. SCHUH and S. STILGENBAUER. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. \textit{haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2018, vol.~103, No~12, p.~1956-1968. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.187583.
|
